{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:56:08Z","timestamp":1784030168140,"version":"3.55.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1053\/j.seminhematol.2021.02.003","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T12:13:49Z","timestamp":1614946429000},"page":"123-129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Primary and secondary central nervous system mature T- and NK-cell lymphomas"],"prefix":"10.1053","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8934-8251","authenticated-orcid":false,"given":"Yifan","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1153-2294","authenticated-orcid":false,"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0001","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1215\/S1522851705000323","article-title":"Temporal trends in incidence of primary brain tumors in the United States, 1985-1999","volume":"8","author":"Hoffman","year":"2006","journal-title":"Neuro Oncol"},{"issue":"Suppl 1","key":"10.1053\/j.seminhematol.2021.02.003_bib0002","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/10428190802311441","article-title":"Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment","volume":"49","author":"Rubenstein","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.003_bib0003","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1038\/leu.2017.128","article-title":"Improved survival in primary central nervous system lymphoma up to age 70 only: a population-based study on incidence, primary treatment and survival in the Netherlands, 1989-2015","volume":"31","author":"van der Meulen","year":"2017","journal-title":"Leukemia"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.003_bib0004","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"10.1053\/j.seminhematol.2021.02.003_bib0005","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0006","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1002\/1097-0142(19830315)51:6<1125::AID-CNCR2820510625>3.0.CO;2-U","article-title":"Primary leptomeningeal presentation of T-cell lymphoma. Report of a patient and review of the literature","author":"Marsh","year":"1983","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.003_bib0007","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3171\/jns.1991.74.4.0668","article-title":"Primary central nervous system T-cell lymphoma. Case report","volume":"74","author":"Bednar","year":"1991","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.003_bib0008","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0009","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1215\/15228517-2008-028","article-title":"Primary central nervous system lymphoma in Japan: changes in clinical features, treatment, and prognosis during 1985-2004","author":"Shibamoto","year":"2008","journal-title":"Neuro-Oncology"},{"issue":"48","key":"10.1053\/j.seminhematol.2021.02.003_bib0010","doi-asserted-by":"crossref","first-page":"28897","DOI":"10.18632\/oncotarget.25622","article-title":"Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis","volume":"9","author":"Chihara","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.003_bib0011","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bjh.14073","article-title":"Trends in primary central nervous system lymphoma incidence and survival in the U.S","volume":"174","author":"Shiels","year":"2016","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.003_bib0012","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/cncr.22989","article-title":"Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003: time trends in a 15-year national survey","volume":"110","author":"Haldorsen","year":"2007","journal-title":"Cancer"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.003_bib0013","doi-asserted-by":"crossref","first-page":"212","DOI":"10.5414\/NP301252","article-title":"CNS lymphoma, the Irish experience: a retrospective review of neuropathologically confirmed cases over 10 years","volume":"39","author":"O'Connell","year":"2020","journal-title":"Clin Neuropathol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.003_bib0014","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF01053274","article-title":"Primary central nervous system lymphoma in Japan\u2013a retrospective, co-operative study by CNS-Lymphoma Study Group in Japan","volume":"19","author":"Hayakawa","year":"1994","journal-title":"J Neurooncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.003_bib0015","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/00000478-200307000-00007","article-title":"Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas","volume":"27","author":"Choi","year":"2003","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.003_bib0016","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1007\/s00277-011-1225-0","article-title":"Primary CNS lymphoma other than DLBCL: a descriptive analysis of clinical features and treatment outcomes","volume":"90","author":"Lim","year":"2011","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.003_bib0017","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1200\/JCO.2005.07.109","article-title":"Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group","volume":"23","author":"Shenkier","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1053\/j.seminhematol.2021.02.003_bib0018","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1097\/PAS.0000000000000503","article-title":"Primary CNS T-cell Lymphomas: a clinical, morphologic, immunophenotypic, and molecular analysis","volume":"39","author":"Menon","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0019","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/s41467-019-10422-7","article-title":"Structural and functional consequences of the STAT5B","volume":"10","author":"de Araujo","year":"2019","journal-title":"Nat Commun"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.003_bib0020","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1158\/1078-0432.CCR-10-1161","article-title":"Primary CNS lymphoma in children and adolescents: a descriptive analysis from the International Primary CNS Lymphoma Collaborative Group (IPCG)","volume":"17","author":"Abla","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0021","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/his.13223","article-title":"Clinicopathological analysis of primary central nervous system NK\/T cell lymphoma: rare and localized aggressive tumour among extranasal NK\/T cell tumours","author":"Miyata-Takata","year":"2017","journal-title":"Histopathology"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0022","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.003_bib0023","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/JCO.2000.18.3.519","article-title":"Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma","volume":"18","author":"O'Brien","year":"2000","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.003_bib0024","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","author":"DeAngelis","year":"1992","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.003_bib0025","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.003_bib0026","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Radiation Therapy Oncology Group S. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.003_bib0027","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3026(17)30174-6","volume":"4","author":"Ferreri","year":"2017","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1053\/j.seminhematol.2021.02.003_bib0028","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.003_bib0029","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.003_bib0030","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.003_bib0031","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.003_bib0032","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0033","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1200\/JCO.2001.19.3.742","article-title":"Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma","author":"Soussain","year":"2001","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.003_bib0034","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.003_bib0035","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1200\/JCO.2006.06.2117","article-title":"High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma","volume":"24","author":"Illerhaus","year":"2006","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.003_bib0036","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mds059","article-title":"Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma\u2013a long-term follow-up study","volume":"23","author":"Kasenda","year":"2012","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.003_bib0037","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","article-title":"High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group","volume":"38","author":"Colombat","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"13","key":"10.1053\/j.seminhematol.2021.02.003_bib0038","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","article-title":"The role of autologous stem cell transplantation in primary central nervous system lymphoma","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.003_bib0039","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.bbmt.2019.01.020","article-title":"High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry","volume":"25","author":"Kondo","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0040","series-title":"Blood","first-page":"8","article-title":"Superiority of thiotepa-containing conditioning regimens in patients with primary diffuse large B-cell lymphoma (DLBCL) of the central nervous system (CNS) undergoing autologous hematopoietic cell transplantation (autoHCT)","author":"Wang","year":"2020"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.003_bib0041","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1093\/annonc\/mdu443","article-title":"Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy","volume":"25","author":"Abramson","year":"2014","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.003_bib0042","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00234-002-0787-x","article-title":"Central nervous system lesions in adult T-cell leukaemia: MRI and pathology","volume":"44","author":"Kitajima","year":"2002","journal-title":"Neuroradiology"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0043","unstructured":"Network NCC. T-cell lymphomas NCCN Evidence Blocks.: National Comprehensive Cancer Network; 2020 [Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/t-cell_blocks.pdf."},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.003_bib0044","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult T-cell leukemia-lymphoma international consensus meeting report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.003_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W","article-title":"Central nervous system involvement in adult T-cell leukemia\/lymphoma","volume":"65","author":"Teshima","year":"1990","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.003_bib0046","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.003_bib0047","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1182\/blood-2011-03-345702","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"118","author":"Bazarbachi","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.seminhematol.2021.02.003_bib0048","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification","volume":"9","author":"L\u00f3pez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"issue":"16","key":"10.1053\/j.seminhematol.2021.02.003_bib0049","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1200\/JCO.2012.44.7524","article-title":"Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors","volume":"31","author":"Mak","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2014-12-616961","article-title":"Central nervous system relapse in peripheral T-cell lymphomas: a Swedish Lymphoma Registry study","volume":"126","author":"Ellin","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.003_bib0051","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3109\/0284186X.2015.1118656","article-title":"Central nervous system involvement in T-cell lymphoma: a single center experience","volume":"55","author":"Gurion","year":"2016","journal-title":"Acta Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.003_bib0052","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0191461","article-title":"The risk of central nervous system relapses in patients with peripheral T-cell lymphoma","volume":"13","author":"Chihara","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.003_bib0053","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1093\/annonc\/mdq645","article-title":"Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma","volume":"22","author":"Yi","year":"2011","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.003_bib0054","doi-asserted-by":"crossref","first-page":"5346","DOI":"10.1182\/blood-2018-99-119980","article-title":"Central Nervous System Relapse in Patients with Peripheral T-cell Lymphoma","volume":"132","author":"Jeong","year":"2018","journal-title":"Blood;"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0055","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.1998.16.1.70","article-title":"Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients","volume":"16","author":"Cheung","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.003_bib0056","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1093\/annonc\/mdp412","article-title":"When do we need central nervous system prophylaxis in patients with extranodal NK\/T-cell lymphoma, nasal type?","volume":"21","author":"Kim","year":"2010","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1053\/j.seminhematol.2021.02.003_bib0057","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1080\/10428194.2020.1804561","article-title":"Central nervous system involvement at diagnosis in extranodal natural killer\/T-cell lymphoma: a single-center study","volume":"61","author":"Wei","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.003_bib0058","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1080\/10428194.2018.1551541","article-title":"Clinical presentation, treatment, and outcomes of patients with central nervous system involvement in extranodal natural killer\/T-cell lymphoma","volume":"60","author":"Nevel","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"22","key":"10.1053\/j.seminhematol.2021.02.003_bib0059","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1182\/blood.2020005026","article-title":"Prediction and prevention of central nervous system relapse in patients with extranodal natural killer\/T-cell lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"11","key":"10.1053\/j.seminhematol.2021.02.003_bib0060","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1007\/s00277-019-03791-y","article-title":"Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma","volume":"98","author":"Yi","year":"2019","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.003_bib0061","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0145-2126(93)90061-O","article-title":"Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia\/lymphoma","volume":"17","author":"Tsukasaki","year":"1993","journal-title":"Leuk Res"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0062","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 \u2013 the Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1053\/j.seminhematol.2021.02.003_bib0063","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/bjc.2014.405","article-title":"A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma","volume":"111","author":"Cheah","year":"2014","journal-title":"Br J Cancer"},{"issue":"Supplement_1","key":"10.1053\/j.seminhematol.2021.02.003_bib0064","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2019-131435","article-title":"Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era","volume":"134","author":"Bobillo","year":"2019","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1053\/j.seminhematol.2021.02.003_bib0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2020-139025","article-title":"Lack of effectiveness of intravenous high-dose methotrexate for prevention of CNS relapse in patients with high-risk DLBCL: a retrospective analysis from Alberta, Canada","volume":"136","author":"Puckrin","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.003_bib0066","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/BF02983215","article-title":"Deoxycoformycin-containing combination chemotherapy for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study (JCOG9109)","volume":"77","author":"Tsukasaki","year":"2003","journal-title":"Int J Hematol"},{"issue":"2","key":"10.1053\/j.seminhematol.2021.02.003_bib0067","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1046\/j.1365-2141.2001.02737.x","article-title":"A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303","volume":"113","author":"Yamada","year":"2001","journal-title":"Br J Haematol"},{"issue":"34","key":"10.1053\/j.seminhematol.2021.02.003_bib0068","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1200\/JCO.2007.11.9958","article-title":"VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801","volume":"25","author":"Tsukasaki","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.003_bib0069","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3324\/haematol.2012.077917","article-title":"Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas","volume":"98","author":"Korfel","year":"2013","journal-title":"Haematologica"},{"issue":"33","key":"10.1053\/j.seminhematol.2021.02.003_bib0070","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary cns involvement: final results of a multicenter phase II trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0071","article-title":"International multi-centre retrospective analysis of outcomes of thiotepa-based autologous stem cell transplantation for secondary CNS lymphoma","author":"Khwaja","year":"2020","journal-title":"EHA Library"},{"issue":"9","key":"10.1053\/j.seminhematol.2021.02.003_bib0072","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.003_bib0073","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1182\/blood-2017-09-806737","article-title":"A phase 1 study of romidepsin and pralatrexate reveals marked activity in relapsed and refractory T-cell lymphoma","volume":"131","author":"Amengual","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0074","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.2019001285","article-title":"Oral 5-azacytidine and romidepsin exhibit marked activity in patients with PTCL: a multicenter phase 1 study","author":"O'Connor","year":"2019","journal-title":"Blood;"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.003_bib0075","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1080\/10428194.2016.1222375","article-title":"Durable clinical remission induced by romidepsin for chemotherapy-refractory peripheral T-cell lymphoma with central nervous system involvement","volume":"58","author":"Chan","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2019.05.014","article-title":"Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib","volume":"83","author":"Tomlinson","year":"2019","journal-title":"Leuk Res"},{"issue":"10","key":"10.1053\/j.seminhematol.2021.02.003_bib0077","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1007\/s00277-016-2746-3","article-title":"ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin","volume":"95","author":"Abid","year":"2016","journal-title":"Ann Hematol"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0078","doi-asserted-by":"crossref","DOI":"10.12659\/AJCR.921657","article-title":"Durable response to brentuximab vedotin-based chemotherapy in refractory hodgkin lymphoma with central nervous system (CNS) involvement","volume":"21","author":"Mocikov\u00e1","year":"2020","journal-title":"Am J Case Rep"},{"key":"10.1053\/j.seminhematol.2021.02.003_bib0079","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fonc.2018.00414","article-title":"Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease","volume":"8","author":"Kamath","year":"2018","journal-title":"Front Oncol"},{"issue":"23","key":"10.1053\/j.seminhematol.2021.02.003_bib0080","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1053\/j.seminhematol.2021.02.003_bib0081","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1080\/10428194.2020.1742903","article-title":"Pembrolizumab immunotherapy for relapsed CNS Lymphoma","volume":"61","author":"Graber","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"10.1053\/j.seminhematol.2021.02.003_bib0082","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK\/T-cell lymphoma failing l-asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0083","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2018","journal-title":"Ann Hematol"},{"issue":"24","key":"10.1053\/j.seminhematol.2021.02.003_bib0084","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.seminhematol.2021.02.003_bib0085","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1186\/s40425-019-0818-3","article-title":"Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient","volume":"7","author":"Pillonel","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1053\/j.seminhematol.2021.02.003_bib0086","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000001158","article-title":"Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma","volume":"84","author":"Houillier","year":"2015","journal-title":"Neurology"},{"issue":"4","key":"10.1053\/j.seminhematol.2021.02.003_bib0087","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/annonc\/mdz032","volume":"30","author":"Ghesquieres","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1053\/j.seminhematol.2021.02.003_bib0088","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/cncr.29103","article-title":"Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma","volume":"121","author":"Toumishey","year":"2015","journal-title":"Cancer"},{"issue":"15","key":"10.1053\/j.seminhematol.2021.02.003_bib0089","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/bloodadvances.2020002270","article-title":"Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial","volume":"4","author":"Ferreri","year":"2020","journal-title":"Blood Adv"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196321000135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:27:35Z","timestamp":1758522455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196321000135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":89,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0037196321000135"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.003","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary and secondary central nervous system mature T- and NK-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2021.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}